Frontline Nivolumab/Chemo Combo Improves Survival in Gastric/GEJ Cancer and Esophageal Adenocarcinoma
Bristol Myers Squibb’s Opdivo improved survival in previously untreated gastric cancer patients in a trial presented at ESMO20.
Read SourceBristol Myers Squibb’s Opdivo improved survival in previously untreated gastric cancer patients in a trial presented at ESMO20.
Read SourceFor press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org
Together, we will defeat stomach cancer.
Together, we will defeat stomach cancer.
MORE INFODONATE